全文获取类型
收费全文 | 399844篇 |
免费 | 27598篇 |
国内免费 | 8967篇 |
专业分类
耳鼻咽喉 | 4348篇 |
儿科学 | 10025篇 |
妇产科学 | 7388篇 |
基础医学 | 30585篇 |
口腔科学 | 8515篇 |
临床医学 | 46152篇 |
内科学 | 46186篇 |
皮肤病学 | 4974篇 |
神经病学 | 20363篇 |
特种医学 | 9526篇 |
外国民族医学 | 33篇 |
外科学 | 39233篇 |
综合类 | 64477篇 |
现状与发展 | 14篇 |
一般理论 | 67篇 |
预防医学 | 53021篇 |
眼科学 | 5883篇 |
药学 | 35182篇 |
720篇 | |
中国医学 | 35257篇 |
肿瘤学 | 14460篇 |
出版年
2023年 | 6415篇 |
2022年 | 11656篇 |
2021年 | 15963篇 |
2020年 | 15256篇 |
2019年 | 20091篇 |
2018年 | 17666篇 |
2017年 | 14852篇 |
2016年 | 12377篇 |
2015年 | 11674篇 |
2014年 | 24590篇 |
2013年 | 26092篇 |
2012年 | 22758篇 |
2011年 | 24421篇 |
2010年 | 19489篇 |
2009年 | 17612篇 |
2008年 | 17512篇 |
2007年 | 17669篇 |
2006年 | 15543篇 |
2005年 | 13213篇 |
2004年 | 10790篇 |
2003年 | 9281篇 |
2002年 | 7287篇 |
2001年 | 6469篇 |
2000年 | 5352篇 |
1999年 | 4561篇 |
1998年 | 3694篇 |
1997年 | 3526篇 |
1996年 | 3028篇 |
1995年 | 2931篇 |
1994年 | 2707篇 |
1993年 | 2146篇 |
1992年 | 2150篇 |
1991年 | 1881篇 |
1990年 | 1678篇 |
1989年 | 1495篇 |
1988年 | 1409篇 |
1987年 | 1203篇 |
1985年 | 3885篇 |
1984年 | 4899篇 |
1983年 | 3418篇 |
1982年 | 3888篇 |
1981年 | 3607篇 |
1980年 | 3222篇 |
1979年 | 2941篇 |
1978年 | 2579篇 |
1977年 | 1958篇 |
1976年 | 2193篇 |
1975年 | 1657篇 |
1974年 | 1444篇 |
1973年 | 1285篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
《Annales médico-psychologiques》2021,179(8):744-747
The teaching and clinical practice of professor Yves Pélicier contributed to the international development of a psychiatry centered on the whole of the person in a humanist approach. The theoretical developments were marked by the authenticity of the practice of the therapist and its deep sense of the human being thus truly founding a School. 相似文献
23.
《Clinical neurophysiology》2021,132(9):2003-2011
ObjectiveA large N20 and P25 of the median nerve somatosensory evoked potential (SEP) predicts short survival in amyotrophic lateral sclerosis (ALS). We investigated whether high frequency oscillations (HFOs) over N20 are enlarged and associated with survival in ALS.MethodsA total of 145 patients with ALS and 57 healthy subjects were studied. We recorded the median nerve SEP and measured the onset-to-peak amplitude of N20 (N20o-p), and peak-to-peak amplitude between N20 and P25 (N20p-P25p). We obtained early and late HFO potentials by filtering SEP between 500 and 1 kHz, and measured the peak-to-peak amplitude. We followed up patients until endpoints (death or tracheostomy) and analyzed the relationship between SEP or HFO amplitudes and survival using a Cox analysis.ResultsPatients showed larger N20o-p, N20p-P25p, and early and late HFO amplitudes than the control values. N20p-P25p was associated with survival periods (p = 0.0004), while early and late HFO amplitudes showed no significant association with survival (p = 0.4307, and p = 0.6858, respectively).ConclusionsThe HFO amplitude in ALS is increased, but does not predict survival.SignificanceThe enlarged HFOs in ALS might be a compensatory phenomenon to the hyperexcitability of the sensory cortex pyramidal neurons. 相似文献
24.
25.
26.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
27.
采用文献复习和实证研究经验的方法对《医疗质量管理办法》中涉及的医疗质量概念及相关问题进行探讨。《医疗质量管理办法》中的医疗质量的定义存在重大缺失,没有涉及医疗服务的结果,特别是患者安全。医疗质量的定义应与国际相关权威机构保持一致,应高度重视医疗服务的结果,特别是患者安全。 相似文献
28.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
29.
30.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献